223 related articles for article (PubMed ID: 29678136)
1. Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study.
Mulders-Manders CM; Kanters TA; van Daele PLA; Hoppenreijs E; Legger GE; van Laar JAM; Simon A; Hakkaart-van Roijen L
Orphanet J Rare Dis; 2018 Apr; 13(1):59. PubMed ID: 29678136
[TBL] [Abstract][Full Text] [Related]
2. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
6. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
Caorsi R; Lepore L; Zulian F; Alessio M; Stabile A; Insalaco A; Finetti M; Battagliese A; Martini G; Bibalo C; Martini A; Gattorno M
Arthritis Res Ther; 2013 Feb; 15(1):R33. PubMed ID: 23442610
[TBL] [Abstract][Full Text] [Related]
7. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
8. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T; Izawa K; Masui S; Yamazaki A; Yamasaki Y; Matsubayashi T; Shiraki M; Ohnishi H; Yasumura J; Kawabe T; Miyamae T; Matsubara T; Arakawa N; Ishige T; Takizawa T; Shimbo A; Shimizu M; Kimura N; Maeda Y; Maruyama Y; Shigemura T; Furuta J; Sato S; Tanaka H; Izumikawa M; Yamamura M; Hasegawa T; Kaneko H; Nakagishi Y; Nakano N; Iida Y; Nakamura T; Wakiguchi H; Hoshina T; Kawai T; Murakami K; Akizuki S; Morinobu A; Ohmura K; Eguchi K; Sonoda M; Ishimura M; Furuno K; Kashiwado M; Mori M; Kawahata K; Hayama K; Shimoyama K; Sasaki N; Ito T; Umebayashi H; Omori T; Nakamichi S; Dohmoto T; Hasegawa Y; Kawashima H; Watanabe S; Taguchi Y; Nakaseko H; Iwata N; Kohno H; Ando T; Ito Y; Kataoka Y; Saeki T; Kaneko U; Murase A; Hattori S; Nozawa T; Nishimura K; Nakano R; Watanabe M; Yashiro M; Nakamura T; Komai T; Kato K; Honda Y; Hiejima E; Yonezawa A; Bessho K; Okada S; Ohara O; Takita J; Yasumi T; Nishikomori R;
Arthritis Rheumatol; 2024 Jun; 76(6):949-962. PubMed ID: 38268504
[TBL] [Abstract][Full Text] [Related]
10. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
11. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study.
Kone-Paut I; Quartier P; Fain O; Grateau G; Pillet P; Le Blay P; Bonnet F; Despert V; Stankovic-Stojanovic K; Willemin L; Quéré S; Reigneau O; Hachulla E
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):903-911. PubMed ID: 27635935
[TBL] [Abstract][Full Text] [Related]
12. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra.
Lepore L; Paloni G; Caorsi R; Alessio M; Rigante D; Ruperto N; Cattalini M; Tommasini A; Zulian F; Ventura A; Martini A; Gattorno M
J Pediatr; 2010 Aug; 157(2):310-315.e1. PubMed ID: 20472245
[TBL] [Abstract][Full Text] [Related]
13. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
14. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
16. Neurologic manifestations of the cryopyrin-associated periodic syndrome.
Kitley JL; Lachmann HJ; Pinto A; Ginsberg L
Neurology; 2010 Apr; 74(16):1267-70. PubMed ID: 20404307
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry.
Walker UA; Tilson HH; Hawkins PN; Poll TV; Noviello S; Levy J; Vritzali E; Hoffman HM; Kuemmerle-Deschner JB;
RMD Open; 2021 May; 7(2):. PubMed ID: 34001647
[TBL] [Abstract][Full Text] [Related]
19. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
[TBL] [Abstract][Full Text] [Related]
20. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
Brogan PA; Hofer M; Kuemmerle-Deschner JB; Koné-Paut I; Roesler J; Kallinich T; Horneff G; Calvo Penadés I; Sevilla-Perez B; Goffin L; Lauwerys BR; Lachmann HJ; Uziel Y; Wei X; Laxer RM
Arthritis Rheumatol; 2019 Nov; 71(11):1955-1963. PubMed ID: 31161734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
